Key Questions RAS Can Help You Answer

  • What is the current solid tumor clinical development landscape?

  • What are the key market impacting events?

  • What´s the strategy of major Oncology players?

  • What´s the positioning and strategy for a molecule of interest?

  • What are the upcoming innovation waves? What are the opportunities created by them?

  • What´s the current state-of-the-art in cancer biomarkers?

  • How to keep pace with the regulatory policies & payer positions across geographies?

  • What drug candidates/ companies are suitable for partnering or in-licensing for oncology therapeutics?

Featured Insights

June 11, 2019 / infographics, Oncology

Is AML Treatment Landscape At A Tipping Point?

The recent flurry of drug approvals has markedly altered the treatment landscape in AML providing patients with new opportunities. The space is getting more exciting as improved genetic testing, combinations of targeted therapies, and the advancement of immunotherapies will finally provide physicians options to advance beyond Walkman-era treatments.
Read More
August 16, 2018 / infographics, Oncology

Evolution In EGFRM+ Lung Cancer

Interest in the EGFR Lung cancer space initially started with the isolation of Epidermal growth factor (EGF) gene by Stanley Cohen in 1962 as a protein extracted from the mouse submaxillary gland that accelerated incisor eruption. Therefore, it was originally termed ‘tooth-lid factor’, but was later renamed EGF because it stimulated the proliferation of epithelial cells. Since then substantial progress has been made against lung cancer over the last two decades. Research has also powered the emergence of new targeted treatments which are helping patients live a longer and higher quality life after a lung cancer diagnosis. This infographic allows the reader to dwell deeper and look closely into the history of discovery, evolution and advancements pertaining to EGFR lung cancer space.
Read More
June 4, 2018 / ASCO18, infographics, Oncology

Major Milestones in Cancer Research

Research and development within the cancer field is continuously evolving and progressing. This infographic highlights the biggest milestones within the field of cancer research spanning 170 years —from the advent of general anesthesia opening the door for cancer surgery in the mid-1800s to the first gene therapy for cancer approved by the Food and Drug Administration in 2017.
Read More
May 25, 2018 / Featured Insights, Oncology

Nanotechnology in Drug Discovery and Design

This presentation takes the reader on an exciting journey, about the Science beneath the development of Oncology Nano Drug delivery systems. How the tumor mico and macro environments throws conspicuous challenges to the nanotech field? Furthermore, the presentation also gives a sneak view of Nanotherapeutics clinical landscape across development strategies and tumors.
Read More
July 18, 2017 / Biosimilars, Featured Insights, Oncology

Oncology Biosimilar Competitive Dynamics

This paper attempts to present situation analysis of the current marketplace of Oncology biosimilars specially with respect to the industry’s micro-environment. The research and analysis herein, intends to identify positive forces and interactions that are shaping an attractive biosimilar industry in both US and EU markets.
Read More

Read Our Blogs

June 14, 2019
AI/ ML

Recommended AI-ML Abstracts from ASCO 2019

Beyond the hype surrounding #ArtificalIntelligence, #MachineLearning and #DeepLearning, there are several serious research groups working on developing AI based technologies to improve healthcare. At ASCO19, several academic and industry groups presented the outcomes of their research in developing tools for improving oncology healthcare. The range of presentations was wide – […]
June 4, 2019
Hepatobiliary-cancer

Recommended Hepatobiliary Cancer Abstracts from ASCO 2019

Related Post Recommended AI-ML Abstracts from ASCO 2019 Recommended Breast Cancer Abstracts from ASCO 2019 Recommended Esophageal/Gastric Cancer Abstracts from ASCO 2019
June 3, 2019
breast-cancer-tumor

Recommended Breast Cancer Abstracts from ASCO 2019

Related Post Recommended AI-ML Abstracts from ASCO 2019 Recommended Hepatobiliary Cancer Abstracts from ASCO 2019 Recommended Esophageal/Gastric Cancer Abstracts from ASCO 2019
June 1, 2019
gastric-cancer

Recommended Esophageal/Gastric Cancer Abstracts from ASCO 2019

Related Post Recommended AI-ML Abstracts from ASCO 2019 Recommended Hepatobiliary Cancer Abstracts from ASCO 2019 Recommended Breast Cancer Abstracts from ASCO 2019
June 1, 2019
Io_resistance

What to expect on I-O Resistance at ASCO 2019?

Related Post Recommended AI-ML Abstracts from ASCO 2019 Recommended Hepatobiliary Cancer Abstracts from ASCO 2019 Recommended Breast Cancer Abstracts from ASCO 2019
August 16, 2018
egfr_lung_cancer

1L EGFRm+ NSCLC competition – Where are we heading to?

1L EGFRm+ Lung cancer is rapidly evolving and changing. Tagrisso is leading the pack with ORR of 77% and PFS of 18.9 mos. However, talking about overall survival, Dacomitinib is currently leading with OS of 34.1 mos. As Tagrioss’s final OS data is yet to be declared, the OS in […]

What would you like to know?